Cipher Pharmaceuticals Inc. (CPHR) Hits New 52-Week Low on Disappointing Earnings
Shares of Cipher Pharmaceuticals Inc. (NASDAQ:CPHR) reached a new 52-week low during mid-day trading on Monday following a weaker than expected earnings announcement. The company traded as low as $2.66 and last traded at $2.66, with a volume of 16,290 shares trading hands. The stock had previously closed at $2.92.
The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by $0.01. The company had revenue of $9.30 million for the quarter, compared to analysts’ expectations of $10.42 million. Cipher Pharmaceuticals had a negative return on equity of 8.75% and a negative net margin of 64.97%.
CPHR has been the subject of several research analyst reports. TD Securities reaffirmed a “buy” rating and set a $7.50 target price on shares of Cipher Pharmaceuticals in a research note on Saturday, August 13th. GMP Securities reissued a “hold” rating on shares of Cipher Pharmaceuticals in a research report on Saturday, August 13th.
The firm’s market cap is $70.99 million. The stock has a 50 day moving average of $3.55 and a 200 day moving average of $4.67.
Cipher Pharmaceuticals Company Profile
Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.
Receive News & Stock Ratings for Cipher Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.